MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2967/jnumed.125.271680

Медицинская библиотека · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026

Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort.

Bauckneht Matteo, Belgioia Liliana, Albano Domenico, Triggiani Luca, Linguanti Flavia, Urso Luca, Mazzola Rosario, Rizzo Alessio, D'Angelo Elisa, Dondi Francesco, Mataj Eneida, Pedersoli Gloria, Abenavoli Elisabetta Maria, Vaggelli Luca, Detti Beatrice, Ortolan Naima, Malorgio Antonio, Guarneri Alessia, Garrou Federico, Passoni Jacopo, Fiorini Matilde, Grimaldi Serena, Ghedini Pietro, Iorio Giuseppe Carlo, Iudicello Antonella, Rovera Guido, Fornarini Giuseppe, Zanardi Elisa, Bongiovanni Diego, Marcenaro Michela, Agosti Alessandra, Timon Giorgia, Salgarello Matteo, Racca Manuela, Bartolomei Mirco, Panareo Stefano, Ricardi Umberto, Bertagna Francesco, Alongi Filippo, Barra Salvina, Morbelli Silvia, Lanfranchi Francesco, Sambuceti Gianmario

СтатьяПеревод в очереди

Аннотация

It is unclear whether the imaging modality used to guide metastasis-directed therapy (MDT) influences outcomes in oligometastatic castration-resistant prostate cancer (omCRPC).

Methods

We performed an updated analysis of the PRECISE-MDT cohort, adding 27 patients to the original cohort. MDT guided by prostate-specific membrane antigen (PSMA) PET/CT, choline PET/CT, and conventional imaging was compared in 102 patients with omCRPC. The primary outcomes were biochemical recurrence-free survival and overall survival after adjustment for inverse probability of treatment weighting.

Results

MDT was guided by conventional imaging in 20 (19.6%) patients, choline PET/CT in 56 (54.9%) patients, and PSMA PET/CT in 26 (25.5%) patients. PSMA PET/CT guidance yielded longer biochemical recurrence-free survival than did choline PET/CT (median not reached [NR] vs. 11.7 mo, P = 0.031) and conventional imaging (NR vs. 7.1 mo, P = 0.002). Overall survival favored PSMA PET/CT versus conventional imaging (NR vs. 46.0 mo, P = 0.036).

Conclusion

PSMA PET/CT guidance was associated with improved clinical outcome, supporting its therapeutic relevance for MDT planning in omCRPC.

Для цитирования: Bauckneht Matteo, Belgioia Liliana, Albano Domenico, Triggiani Luca, Linguanti Flavia, Urso Luca, Mazzola Rosario, Rizzo Alessio, D'Angelo Elisa, Dondi Francesco, Mataj Eneida, Pedersoli Gloria, Abenavoli Elisabetta Maria, Vaggelli Luca, Detti Beatrice, Ortolan Naima, Malorgio Antonio, Guarneri Alessia, Garrou Federico, Passoni Jacopo, Fiorini Matilde, Grimaldi Serena, Ghedini Pietro, Iorio Giuseppe Carlo, Iudicello Antonella, Rovera Guido, Fornarini Giuseppe, Zanardi Elisa, Bongiovanni Diego, Marcenaro Michela, Agosti Alessandra, Timon Giorgia, Salgarello Matteo, Racca Manuela, Bartolomei Mirco, Panareo Stefano, Ricardi Umberto, Bertagna Francesco, Alongi Filippo, Barra Salvina, Morbelli Silvia, Lanfranchi Francesco, Sambuceti Gianmario. Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2026. DOI: 10.2967/jnumed.125.271680.

Предметные рубрики MeSH

HumansMaleProstatic Neoplasms, Castration-ResistantPositron Emission Tomography Computed TomographyNeoplasm MetastasisTreatment OutcomeAgedCohort StudiesMiddle AgedCholineAged, 80 and over
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.